NCT07828093

Brief Summary

The purpose of this study is to analyze changes in the gut microbiota of healthy adult athletes, both men and women, before and after supplementation with a dietary fiber (agavins). Each participant will be their own control, so the design will allow us to identify whether the intervention generates changes in bacterial composition and whether these changes are related to variations in physical performance. The study will determine changes in the gut microbiota, athletic performance, and markers of metabolic stress such as lactate and creatine kinase. Volunteers will be required to take 10g of agavins in warm water for 6 weeks. The gut microbiota will be evaluated through a stool sample, while athletic performance will be measured through direct calorimetry, determining VO2max. Lactate will be determined by finger prick using Accutrend Plus equipment, while creatine kinase will be measured using a blood sample taken by staff from the biomarker measurement laboratory of the Department of Nutrition and Functional Foods.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for not_applicable

Timeline
5mo left

Started Jun 2025

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress79%
Jun 2025Feb 2027

Study Start

First participant enrolled

June 6, 2025

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

August 14, 2026

Completed
1 month until next milestone

First Posted

Study publicly available on registry

September 18, 2026

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 11, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 11, 2027

Last Updated

September 18, 2026

Status Verified

September 1, 2026

Enrollment Period

1.7 years

First QC Date

August 14, 2026

Last Update Submit

September 15, 2026

Conditions

Keywords

sportsmicrobiotadietetic fiberagavinsathlete

Outcome Measures

Primary Outcomes (1)

  • Changes in the relative abundance of gut microbiota bacterial taxa determined by multiplex digital PCR

    The relative abundance of selected gut microbiota bacterial taxa will be determined from fresh fecal samples collected at baseline and after 6 weeks of supplementation using multiplex digital PCR and reported as percentages of the total bacterial population.

    Before and after agavin supplementation, which lasts 6 weeks

Secondary Outcomes (3)

  • Changes in metabolic stress markers (serum creatine kinase and blood lactate concentrations)

    Before and after agavin supplementation, which lasts 6 weeks

  • Change in maximal oxygen consumption (VO₂max; mL/kg/min)

    before and after the agave treatment, which lasts 6 weeks

  • Change in body composition

    before and after the intervention, which lasts six weeks

Study Arms (1)

agavins

EXPERIMENTAL

Intervention group that is its own control

Dietary Supplement: Agavins

Interventions

AgavinsDIETARY_SUPPLEMENT

tomarán 10 g en ayudas diariamente

Also known as: dietetic fiber, agave inulin
agavins

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • athletes in any sport, metabolically healthy.

You may not qualify if:

  • intestinal diseases, recreational athletes, people undergoing antibiotic treatment, people undergoing treatment with probiotics or prebiotics.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centro de Desarrollo de Productos Bióticos

Yautepec, Morelos, 62739, Mexico

Location

MeSH Terms

Conditions

Dysbiosis

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Perla Osorio, SNI II

    Centro de Desarrollo de Productos Bióticos

    STUDY DIRECTOR
  • Brenda H Camacho, Díaz

    Centro de Desarrollo de Productos Bióticos

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
phD student

Study Record Dates

First Submitted

August 14, 2026

First Posted

September 18, 2026

Study Start

June 6, 2025

Primary Completion (Estimated)

February 11, 2027

Study Completion (Estimated)

February 11, 2027

Last Updated

September 18, 2026

Record last verified: 2026-09

Data Sharing

IPD Sharing
Will share

De-identified individual participant data underlying the published results will be available. Shared data may include demographic, anthropometric, gut microbiota, short-chain fatty acid, cardiorespiratory fitness, blood biochemical, and statistical analysis data collected before and after the intervention. Personal identifiers will be removed. De-identified data will be available upon reasonable request to the principal investigator for researchers with an approved scientific proposal. Data will be shared after publication of the primary study results.

Shared Documents
CSR

Locations